ImmunityBio, Inc. (IBRX)
7.80
-0.07
(-0.89%)
USD |
NASDAQ |
Sep 02, 11:06
ImmunityBio Cash from Investing (Quarterly) : -107.47M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -107.47M |
| March 31, 2026 | -31.65M |
| December 31, 2025 | 43.57M |
| September 30, 2025 | -181.36M |
| June 30, 2025 | -16.14M |
| March 31, 2025 | 4.129M |
| December 31, 2024 | 9.834M |
| September 30, 2024 | 65.03M |
| June 30, 2024 | -51.49M |
| March 31, 2024 | -35.62M |
| December 31, 2023 | 2.249M |
| September 30, 2023 | -15.63M |
| June 30, 2023 | -8.604M |
| March 31, 2023 | -8.484M |
| December 31, 2022 | -18.89M |
| September 30, 2022 | -1.168M |
| June 30, 2022 | 116.67M |
| March 31, 2022 | -69.31M |
| December 31, 2021 | -137.80M |
| September 30, 2021 | 10.58M |
| June 30, 2021 | 10.49M |
| March 31, 2021 | 31.84M |
| December 31, 2020 | 6.568M |
| September 30, 2020 | -56.25M |
| June 30, 2020 | 14.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 14.16M |
| December 31, 2019 | 12.16M |
| September 30, 2019 | 17.37M |
| June 30, 2019 | 11.38M |
| March 31, 2019 | -19.46M |
| December 31, 2018 | 15.91M |
| September 30, 2018 | 16.87M |
| June 30, 2018 | 21.39M |
| March 31, 2018 | 2.92M |
| December 31, 2017 | 19.73M |
| September 30, 2017 | 6.961M |
| June 30, 2017 | 56.82M |
| March 31, 2017 | 16.04M |
| December 31, 2016 | -8.464M |
| September 30, 2016 | 6.855M |
| June 30, 2016 | -10.15M |
| March 31, 2016 | -101.91M |
| December 31, 2015 | -171.98M |
| September 30, 2015 | -0.672M |
| June 30, 2015 | 4.753M |
| March 31, 2015 | -7.326M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | -0.002M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Moderna, Inc. | 329.00M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -66.49M |
| Cash from Financing (Quarterly) | 44.44M |
| Free Cash Flow | -288.51M |
| Free Cash Flow Per Share (Quarterly) | -0.0667 |
| Free Cash Flow to Equity (Quarterly) | -173.83M |
| Free Cash Flow to Firm (Quarterly) | -38.79M |
| Free Cash Flow Yield | -3.69% |